Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
Adult
Animals
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
COVID-19
/ immunology
COVID-19 Vaccines
/ immunology
Cell Line
Chlorocebus aethiops
Female
Humans
Immune Evasion
/ immunology
Male
Middle Aged
Neutralization Tests
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
Vaccination
Vaccines, Inactivated
/ immunology
Vero Cells
Young Adult
CoronaVac vaccine
SARS-CoV-2 variants
neutralizing antibodies
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
23
07
2021
accepted:
27
08
2021
pubmed:
31
8
2021
medline:
24
11
2021
entrez:
30
8
2021
Statut:
ppublish
Résumé
Vaccination generates a neutralizing immune response against SARS-CoV-2. The genomic surveillance is showing the emergence of variants with mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we report the neutralization potency against alpha, gamma, and D614G SARS-CoV-2 variants in 44 individuals that received two doses of CoronaVac vaccine, an inactivated SARS-CoV-2 vaccine. Plasma samples collected at 60 days after the second dose of CoronaVac were analyzed by the reduction of cytopathic effect in Vero E6 cells with the three infectious variants of SARS-CoV-2. Plasma showed lower neutralization with alpha (geometric mean titer [GMT] = 18.5) and gamma (GMT = 10.0) variants than with D614G (GMT = 75.1) variant. Efficient neutralization against the alpha and gamma variants was not detected in 31.8% and 59.1% of plasma, respectively. These findings suggest the alpha and gamma variants could escape from neutralization by antibodies elicited by vaccination. Robust genomic and biological surveillance of viral variants could help to develop effective strategies for the control of SARS-CoV-2.
Identifiants
pubmed: 34460119
doi: 10.1002/jmv.27310
pmc: PMC8662277
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Inactivated
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
399-403Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Emerg Infect Dis. 2021 Jul;27(7):1789-1794
pubmed: 33883059
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Cell Host Microbe. 2021 Apr 14;29(4):522-528.e2
pubmed: 33789085
Lancet Microbe. 2021 Jul;2(7):e283-e284
pubmed: 33846703
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Nat Med. 2021 Apr;27(4):620-621
pubmed: 33558724
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
Lancet Microbe. 2021 Oct;2(10):e527-e535
pubmed: 34258603
J Med Virol. 2022 Jan;94(1):399-403
pubmed: 34460119
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
J Med Virol. 2021 Jul;93(7):4334-4341
pubmed: 33713457
Vaccines (Basel). 2020 Dec 28;9(1):
pubmed: 33379160